Sustained hemostatic abnormality in patients with steroid-induced osteonecrosis in the early period after high-dose corticosteroid therapy

2000 ◽  
Vol 5 (4) ◽  
pp. 374-379 ◽  
Author(s):  
Kazuhiro Oinuma ◽  
Yoshitada Harada ◽  
Yasushi Nawata ◽  
Katsuhiko Takabayashi ◽  
Isao Abe ◽  
...  
Keyword(s):  
Corticosteroid Therapy ◽  
Early Period ◽  
High Dose ◽  
High Dose Corticosteroid ◽  
Dose Corticosteroid

Ethosuximide-induced Stevens-Johnson syndrome: Beneficial effect of early intervention with high-dose corticosteroid therapy

2018 ◽  
Vol 45 (5) ◽  
pp. 592-595 ◽  
Author(s):  
Kota Tachibana ◽  
Toshihisa Hamada ◽  
Hiroki Tsuchiya ◽  
Takashi Shibata ◽  
Kazuyasu Fujii ◽  
...  
Keyword(s):  
Early Intervention ◽  
Beneficial Effect ◽  
Corticosteroid Therapy ◽  
Stevens Johnson Syndrome ◽  
High Dose ◽  
High Dose Corticosteroid ◽  
Johnson Syndrome ◽  
Dose Corticosteroid

Bone Complications of Corticosteroids

1996 ◽  
Vol 1 (1) ◽  
pp. 50-57 ◽  
Author(s):  
Robert S. Lester
Keyword(s):  
Corticosteroid Therapy ◽  
Low Dose ◽  
Treatment Options ◽  
Osteoporotic Fractures ◽  
High Dose ◽  
Systemic Complications ◽  
High Dose Corticosteroid ◽  
Systemic Corticosteroids ◽  
Dose Corticosteroid ◽  
Bone Complications

Background: Systemic corticosteroids, a mainstay of treatment for severe dermatosis, are associated with systemic complications. Adverse effects of corticosteroids to bone represent a significant adverse effect that, is poorly understood and poorly managed. Objectives: The purpose of this article is to educate dermatologists to the current understanding of the pathogenesis, diagnosis, and treatment options available for bone complications of corticosteroids. Results: Virtually all patients chronically exposed to high-dose corticosteroid therapy lose bone mass and are at risk for osteoporotic fractures. In addition, osteonecrosis is an unpredictable complication of corticosteroid therapy that may occur with even low-dose corticosteroids. Conclusion: Optimal risk management of corticosteroid therapy includes understanding the risk factors associated with bone complications and improving communication with patients.

Myelofibrosis and Systemic Lupus erythematosus: Reversal of Fibrosis with High-Dose Corticosteroid Therapy

1992 ◽  
Vol 88 (1) ◽  
pp. 32-36 ◽  
Author(s):  
Yasushi Inoue ◽  
Atsushi Matsubara ◽  
Shigeru Okuya ◽  
Koichiro Okafuji ◽  
Kohei Kaku ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Corticosteroid Therapy ◽  
Lupus Erythematosus ◽  
High Dose ◽  
Systemic Lupus ◽  
High Dose Corticosteroid ◽  
Dose Corticosteroid
Sign in / Sign up

Export Citation Format

Share Document